<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05038007</url>
  </required_header>
  <id_info>
    <org_study_id>AAUH-VATS-01</org_study_id>
    <nct_id>NCT05038007</nct_id>
  </id_info>
  <brief_title>Pain After Lung Cancer Surgery - Comparing Traditional Versus Prolonged Release Nerve Blockades</brief_title>
  <official_title>Pain After Thoracoscopic Lung Surgery - the Effect of Intercostal Nerve Blockades With Standard Bupivacaine and Liposomal Bupivacaine - a Randomised Controlled Feasibility Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jannie Bisgaard Stæhr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of liposomal bupivacaine compared with bupivacaine hydrochloride&#xD;
      for intercostal blockades for patients undergoing Video-assisted thoracoscopic surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Video-assisted thoracoscopic surgery (VATS) is a minimally invasive routine procedure. It's&#xD;
      less invasive than thoracotomy but postoperative pain is still a problem.&#xD;
&#xD;
      At Aalborg University Hospital, intercostal blockades with bupivacaine is used as standard&#xD;
      pain treatment for patients undergoing VATS. Adding adjuvants to the blockades may prolong&#xD;
      the effect.&#xD;
&#xD;
      The aim of this study is to examine if intercostal nerve blockades with liposomal bupivacaine&#xD;
      improves postoperative pain management compared to intercostal nerve blockades with&#xD;
      bupivacaine hydrochloride.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of analgesic effect</measure>
    <time_frame>48 hours</time_frame>
    <description>Time in hours to first postoperative administration of Pro Re Nata (PRN) opioids</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total equipotent opioid dose</measure>
    <time_frame>48 hours</time_frame>
    <description>Total equipotent opioid dose in milligrams during the first 48 hours after surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain intensity on a Numerical Rating Scale ranging from 0 indicating no pain to 10 indicating worst pain imaginable during the first two postoperative days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobilisation</measure>
    <time_frame>48 hours</time_frame>
    <description>Time in hours to full mobilisation defined as walking with or without aids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioids at discharge</measure>
    <time_frame>Not fixed. On average 4 days and a maximum of 3 months.</time_frame>
    <description>Need for opioids at discharge (yes or no and equipotent dosage)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported satisfaction of postoperative pain management assessed by self-made questionnaire in Danish</measure>
    <time_frame>Measured twice. Once 48 hours after surgery and once at non fixed time(on average 4 days and a maximum of 3 months)</time_frame>
    <description>Patients are asked to fill out a questionnaire rating their general satisfaction with pain management and sufficiency of pain treatment on a scale from 0 to 10. The questionnaire also assess whether the patients had any perceived side effects and how uncomfortable they were on a scale from 0 to 10.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Postoperative Pain</condition>
  <condition>Lung Cancer</condition>
  <condition>Video Assisted Thoracoscopic Surgery</condition>
  <condition>Blockades Neuromuscular</condition>
  <condition>Anesthesia, Local</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bupivacaine Hydrochloride in perioperative intercostal blockades</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal bupivacaine in perioperative intercostal blockades</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>As prior described</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <description>As prior described</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults independent of sex with an age of ≥ 18 years&#xD;
&#xD;
          -  Patients undergoing VATS as a part of either examination or treatment of lung cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unable to understand oral and written information.&#xD;
&#xD;
          -  Patients with known chronic pain in the thorax which have been persisting for at least&#xD;
             six months before the day of surgery.&#xD;
&#xD;
          -  Pregnant and nursing women.&#xD;
&#xD;
          -  Patients with hypersensitivity / allergy / Intolerance to dexamethasone or&#xD;
             bupivacaine.&#xD;
&#xD;
          -  Patients receiving a planned preoperative epidural blockade during their stay.&#xD;
&#xD;
          -  Patients converted to open surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jannie Bisgaard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University Hospital, department of Anaesthesiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jannie Bisgaard, MD, PhD</last_name>
    <phone>97660578</phone>
    <phone_ext>0045</phone_ext>
    <email>j.staehr@rn.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Phillip Sperling, BSc</last_name>
    <phone>21141411</phone>
    <phone_ext>0045</phone_ext>
    <email>phis@rn.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <state>Region Of Northern Jutland</state>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University Hospital</investigator_affiliation>
    <investigator_full_name>Jannie Bisgaard Stæhr</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

